|
Oxford Biomedica PLC on Monday announced the launch of fast-track offering for adeno-associated viral vectors and lentiviral vector platforms. The Oxford, England-based gene and cell therapy developer said the launch speeds up viral vector development and manufacture. Oxford Biomedica said: ‘For the manufacture of lentiviral vectors, OXB’s fast-track offering accelerates an industry-standard 12-18 month timeline to as little as nine months, through the use of platform datasets and advanced analytics, and proceeding directly from scale-down models into GMP manufacturing. Additional efficiencies are achieved through the integration of vector design, production, purification, and fill-finish, shortening timelines.’ Chief Business Officer Sebastien Ribault said: ‘For emerging cell and gene therapy companies, viral vector development and manufacture represents a frequent bottleneck to clinical readiness, and issues can delay critical clinical milestones. The launch of our fast-track offering will make our proprietary inAAVate and LentiVector platforms accessible to a wider range of clients who are looking for an expedited route to good manufacturing practice [GMP] manufacture and the clinic, cutting industry standard development timelines by up to 50%.’ Oxford Biomedica shares were 0.4% lower at 564.00 pence each on Monday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
